Anti-Human CD19 (Loncastuximab) [Clone ADCT-402] - 1 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

CD19 is a 95 kDa type I transmembrane glycoprotein found on the surface of B cells at all stages oftheir growth into plasma cells. It works as a co-receptor alongside the B cell receptor (BCR) and isessential in activating, growing, and transforming B cells. CD19 assists in lowering the threshold forBCR signaling, making B cells more sensitive to antigens. Because of its crucial involvement in thelife of B cells, CD19 is an important marker for identifying B cell lineage and is a target fortreatments focusing on B cell-related cancers1-7. ADCT-402, also known as loncastuximab tesirine, is an antibody-drug conjugate (ADC) that targetsCD19-expressing cells. It is made up of a humanized monoclonal antibody that targets CD19 and islinked to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. When ADCT-402 binds to CD19-expressing cells, it is taken inside the cell, and the cytotoxin is released, leading to DNA crosslinkingand cell death. This targeted approach allows for strong and selective anti-tumor activity againstCD19-expressing blood cancers, such as B-cell lymphomas and leukemias8, 9. This non-therapeutic biosimilar is not a drug conjugate and thus does not contain the cytotoxin PDB.

≥ 5.0 mg/ml

CD19 is expressed on all B lineage cells, from early pre-B cells to mature Bcells.